Track market-moving stories before they get noisy

Exelixis (EXEL -1.19%) has crushed the broader market this year, with its shares climbing 49%. However, the drugmaker recently hit a roadblock. The U.S. Food and Drug Administration (FDA) decided to extend the review period for Exelixis' zanzalintinib, an investigational medicine for colorectal cancer. The health regulatory agency requested more data before it can decide whether to approve the drug. A decision is now expected by March 3, 2027, pushed back from the original deadline of Dec. 3, 2026. That's not great news for Exelixis, but despite this setback, the company's prospects look attractive. Here are three reasons why.

Image source: The Motley Fool.

1. Winning the Cabometyx patent battle Exelixis' most important driver of revenue and earnings growth is Cabometyx, a medicine approved for various cancers, including liver and kidney cancers. Cabometyx is a tyrosine kinase inhibitor -- tyrosine kinase is a protein that plays a role in cell growth and division, a mechanism that is sometimes hijacked by cancer cells to promote rapid growth. Cabometyx has been one of the top-prescribed medicines of its kind in renal cell carcinoma (RCC, the most common form of kidney cancer) for years.

It has also continued to grind out new indications, including as a combination therapy. Exelixis' financial results have been strong thanks to this drug. In the second quarter, the company's revenue increased by 10.6% year over year to $628.7 million. Exelixis' earnings per share grew by about 26% year over year to $0.82.

Exelixis has done its best to delay the entry of cheaper Cabometyx generics in the U.S., and so far, it has been successful. Thanks to a patent lawsuit it won, it should not face generic competition in the U.S. at least until January 2030, perhaps even later if the company wins another patent case that starts in November. That should give Exelixis enough time to develop newer medicines to replace its crown jewel.

EXEL Exelixis$64.53-$0.78 (-1.19%)

NASDAQ · As of 4:00 PM ET 10/23/26

2. Zanzalintinib could be a pipeline-in-a-drug The most promising drug Exelixis is developing is zanzalintinib, and that's despite the recent regulatory setback. Consider the medicine's potential in colorectal cancer. It is the second leading cause of cancer death worldwide, which implies that there is a large opportunity in the market, particularly for the indication Exelixis is targeting: once it has metastasized. Further, Exelixis won't stop at this indication.

The biotech company will seek to follow the same blueprint it used for Cabometyx. Exelixis is testing zanzalintinib across several other forms of cancer. The list includes RCC, some kinds of lung cancer, and more. Of course, zanzalintinib won't earn every indication it targets. Cabometyx didn't either. But even a handful or so could make the medicine a massive commercial success and help usher in the next phase of growth for Exelixis.

Some analysts have estimated that zanzalintinib could generate $4.5 billion in U.S. sales by 2033 across various indications. Note that last year, the company made $2.3 billion in revenue, mostly from Cabometyx. Provided the sales estimates for zanzalintinib are accurate, this drug could eventually more than offset the loss of Cabometyx.

3. Exelixis' deep pipeline Even if zanzalintinib alone isn't enough to replace Cabometyx once the latter starts facing generic competition, Exelixis has a plan. The company boasts several other pipeline candidates that could eventually contribute. Although these are mostly still in early stage studies, they could make significant progress over the next five years. Most early stage candidates never make it to the market, but there is a decent chance that at least a couple of Exelixis' brand-new therapies will.

And even if none does, the company has research collaborations in place that could supply additional, oncology-focused drug candidates to its pipeline. Exelixis' ability to carve out a niche in the ruthlessly competitive oncology market, which is typically dominated by pharmaceutical giants, is fairly impressive. And over the medium term, the company could, once again, launch one or two brand-new cancer drugs that will help it sustain strong financial results and deliver competitive stock market returns.

Exelixis Reports Solid Earnings—Are New Highs Back on the Table?Exelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer.

Speaking at Morgan Stanley’s Global Healthcare Conference, Morrissey said innovation originating in China has become an important consideration for the biotechnology industry. Exelixis is evaluating external opportunities, including assets from outside the United States, but is prioritizing novel programs over “fast followers” or “me-too” products.

Get Exelixis alerts:

3 Stocks to Buy for a Soft Landing, If There Is One“We are open for business and looking very clearly at trying to expand our portfolio of franchises,” Morrissey said. He added that collaborative arrangements generally make the most sense for the company, though it may also consider acquisitions or partnerships.

AI Use Focused on Curated Data Morrissey said Exelixis is adopting artificial intelligence in a measured way rather than broadly increasing spending across its operations. The company is targeting uses of AI where it has highly curated data sets, including data from discovery, clinical development and commercial activities.

3 Strong Biotech Performers To Watch As Sector Nears BreakoutHe said the company has accumulated decades of longitudinal data and is using AI to improve the speed, depth and utility of its analyses. Commercial applications may be particularly valuable, he said, while security remains a core consideration alongside speed and data quality.

“I do not think we’re spending a lot of money, but I think we’re doing the right level of investments and the right focusing in terms of priorities to maximize impact,” Morrissey said.

On policy, Morrissey said drug pricing and most-favored-nation issues are among the leading concerns for Exelixis and the broader industry. He said the regulatory and political environment remains highly dynamic, with potential changes in Congress and future administrations creating uncertainty. The company maintains a policy team in Washington and engages with lawmakers on pricing, regulatory issues and competitive threats, he said.

Cabozantinib Remains a Major Growth Driver Morrissey said Exelixis’ cabozantinib business remains strong, with a global annualized run rate above $3 billion based on the company’s second-quarter 2026 results. Cabozantinib has been evaluated in numerous pivotal trials and has approvals across eight indications, he said.

The company recently added neuroendocrine tumors, or NET, to the cabozantinib franchise. Morrissey said growth in the indication has been somewhat slower than expected but does not change Exelixis’ long-term outlook.

Exelixis has settled with several generic manufacturers on a Jan. 1, 2031, entry date for cabozantinib. The company continues to litigate with other challengers and said a recent appellate decision supported its position. Morrissey said the company is not particularly concerned about potential 505(b)(2) competitors, which he said would face difficulty gaining adoption without significant clinical investment and data.

Zanzalintinib Launch Preparation Continues Exelixis is preparing to launch zanzalintinib in metastatic colorectal cancer following the STELLAR-303 study. Morrissey said the regulatory review timeline was extended, with the company setting the PDUFA date to March 3, as disclosed in a recent filing. He did not provide additional details beyond the company’s 8-K filing.

The delay has not changed Exelixis’ confidence in the opportunity or its resource allocation, Morrissey said. The company considers itself launch-ready and had previously expanded its gastrointestinal sales force in anticipation of a colorectal cancer launch.

Morrissey said STELLAR-303 was the only successful study among five recent trials testing checkpoint-based platform therapies in third-line or later non-MSI-high colorectal cancer. The trial evaluated zanzalintinib in combination with atezolizumab.

He said the company believes zanzalintinib’s kinase inhibition profile can affect multiple components of the tumor microenvironment, including tumor vasculature and immune cells. Exelixis views the STELLAR-303 results and its STELLAR-316 maintenance-focused trial as complementary parts of a broader colorectal cancer franchise strategy.

The late-line colorectal cancer setting represents approximately 23,000 patients and a $1.5 billion opportunity, according to the Morgan Stanley moderator. Morrissey said Exelixis has substantial overlap with its existing commercial infrastructure and is using sales, marketing and analytics capabilities to support the expected launch.

Broader Development Programs In renal cell carcinoma, Morrissey said STELLAR-304 is the first global randomized pivotal trial in non-clear-cell disease, an area he described as understudied. The trial uses sunitinib as a control arm. Exelixis is also conducting studies of zanzalintinib with belzutifan through its collaboration with Merck.

Morrissey said Exelixis is exploring additional frontline combinations, including possible bispecific antibodies and cancer vaccines. The company has an investigator-sponsored trial with Dana-Farber evaluating zanzalintinib alongside a peptide vaccine program.

For NET, he said STELLAR-311 is comparing zanzalintinib directly with everolimus, unlike the placebo-controlled CABINET trial for cabozantinib. Morrissey said the study is enrolling ahead of schedule and could expand the NET opportunity rather than simply transition existing cabozantinib patients.

Exelixis also has early-stage antibody-drug conjugate, small-molecule and bispecific programs advancing toward development decisions. Morrissey said the company will remain data-driven in determining whether to advance or discontinue programs, regardless of whether an asset originated internally or through business development.

“We just need a small number of winners,” Morrissey said. “We don’t need a big pipeline of unknowns.”

About Exelixis (NASDAQ:EXEL)Exelixis, Inc NASDAQ: EXEL is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company's research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis' principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Exelixis Right Now?Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Integrated Wealth Concepts LLC reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,636 shares of the biotechnology company’s stock after selling 20,265 shares during the period. Integrated Wealth Concepts LLC’s holdings in Exelixis were worth $3,190,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. BlackRock Inc. bought a new position in shares of Exelixis in the 2nd quarter valued at $1,581,991,000. California State Teachers Retirement System lifted its position in shares of Exelixis by 4,875.6% during the 2nd quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company’s stock worth $804,472,000 after buying an additional 14,488,217 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Invesco Ltd. boosted its stake in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock valued at $265,379,000 after buying an additional 94,218 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Exelixis by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after purchasing an additional 39,920 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance EXEL stock opened at $56.12 on Monday. The stock has a market cap of $13.91 billion, a P/E ratio of 17.65, a P/E/G ratio of 1.67 and a beta of 0.42. The stock’s fifty day simple moving average is $55.35 and its two-hundred day simple moving average is $50.02. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $59.72.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same quarter in the previous year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year. Insiders Place Their Bets In related news, Director Mary Beckerle sold 9,812 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the sale, the director directly owned 16,079 shares in the company, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

Analyst Ratings Changes Several equities research analysts recently weighed in on the company. Barclays boosted their price objective on Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Exelixis in a research note on Thursday, July 2nd. BMO Capital Markets initiated coverage on Exelixis in a research note on Tuesday, August 18th. They set a “market perform” rating and a $54.00 target price for the company. William Blair restated an “outperform” rating on shares of Exelixis in a report on Friday. Finally, Wall Street Zen downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $50.07.

Get Our Latest Research Report on Exelixis

Exelixis News Summary Here are the key news stories impacting Exelixis this week:

Neutral Sentiment: The FDA extended its review of Exelixis’ application for zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer by three months. The new decision target is March 2027. The extension does not indicate a rejection, but it delays regulatory clarity. U.S. FDA extends review of Exelixis’ cancer drug Negative Sentiment: The delayed decision pushes back the potential launch and commercial ramp of zanzalintinib in colorectal cancer, reducing near-term visibility for investors and contributing to concern about Exelixis’ revenue outlook. Analysts are also assessing the effect of the announcement on stock volatility. Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In Neutral Sentiment: The FDA action follows Exelixis’ broader investor presentation and legal developments, but the reports provide no new change to the company’s existing earnings outlook or indication of a problem with its currently marketed products. Exelixis Presents at Citigroup’s Biopharma Back to School Summit 2026 Exelixis Company Profile (Free Report)

Exelixis, Inc (NASDAQ: EXEL) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.

Featured Articles Five stocks we like better than Exelixis Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

A month has gone by since the last earnings report for Exelixis (EXEL - Free Report) . Shares have added about 13.3% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View

Exelixis reported adjusted earnings per share (EPS) of 91 cents in the second quarter, which comfortably beat the Zacks Consensus Estimate of 86 cents. The company posted adjusted EPS of 75 cents in the year-ago quarter. Adjusted earnings excluded the impact of stock-based compensation expenses.

Including stock-based compensation expense, EPS was 82 cents compared with 65 cents in the year-ago period.

The bottom-line growth can be attributed to higher operating income and a decrease in shares outstanding due to ongoing buybacks.

Revenues rose 10.6% year over year to $628.7 million but missed the Zacks Consensus Estimate of $635 million.

EXEL's Product Sales Maintain Growth

Net product revenues increased to $573.03 million from $520.01 million in the year-ago quarter, primarily due to higher sales volume.

Cabometyx (cabozantinib) generated revenues of $570.6 million, which missed the Zacks Consensus Estimate of $578 million and our model estimate of $575 million. The drug is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma.

Cabometyx remained the leading prescribed tyrosine kinase inhibitor (TKI) in RCC. Its total prescription share within the company’s tracked oral TKI market basket increased to 47% from 45% a year earlier, while prescription volume rose 12%, outpacing the market basket’s 6% growth.

In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET). The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET).  

However, the neuroendocrine tumor indication expanded more gradually than management had projected. Exelixis attributed the slower ramp-up to the relatively indolent nature of NET, less frequent patient scans and longer transitions between therapies.

Cometriq (cabozantinib capsules) generated $2.4 million in net product revenues for treating medullary thyroid cancer.  

Collaboration revenues rose 15.4% to $55.7 million. The improvement reflected higher royalties on cabozantinib sales outside the United States by partner Ipsen, partly offset by lower development cost reimbursements. Exelixis earned $53.2 million in royalty revenues from partners Ipsen and Takeda during the quarter.

EXEL's Costs Rise as Operating Income Expands

Research and development expenses increased 5.8% year over year to $211.99 million due to higher clinical trial, manufacturing and collaboration costs as Exelixis continued investing in zanzalintinib and other pipeline candidates.

Selling, general and administrative expenses rose 9.5% to $147.63 million, reflecting higher marketing and personnel costs. Despite the increased spending, operating income climbed 16.3% to $248.41 million, and the operating margin expanded to 39.5% from 37.6%.

Exelixis Lowers Its 2026 Revenue Outlook

Management lowered its 2026 total revenue guidance to $2.50-$2.55 billion from $2.525-$2.625 billion. Net product revenue guidance was lowered to $2.30-$2.35 billion from $2.325-$2.425 billion, primarily because of the slower-than-expected NET ramp-up.

The revised outlook excludes potential revenues from zanzalintinib in previously treated metastatic colorectal cancer. Exelixis also lowered its R&D expense forecast to $825-$875 million from $875-$925 million. Its SG&A expense projection remained unchanged at $575-$625 million.

EXEL Advances Share Repurchase Program

Exelixis repurchased $311.6 million of the company’s shares in the second quarter, completing the $750 million share repurchase program (SRP) launched in October 2025.

The company also began repurchases under a new $750 million SRP authorized in May 2026, which runs through Dec. 31, 2027. Since launching its first SRP in March 2023, Exelixis has repurchased $2.9 billion of stock, retiring 93.3 million shares at an average price of $31.12 per share as of the end of the second quarter of 2026.

EXEL Advances Its Zanzalintinib Pipeline

The FDA is reviewing zanzalintinib in combination with Roche’s Tecentriq for previously treated metastatic colorectal cancer, with a target action date of Dec. 3, 2026. Its approval would establish zanzalintinib as Exelixis’ second commercial oncology franchise and broaden its portfolio beyond cabozantinib.

In June 2026, Exelixis reported final phase III STELLAR-303 results showing a non-statistically significant overall survival trend favoring zanzalintinib plus Tecentriq over regorafenib in the non-liver metastases (NLM) subgroup of previously treated non-MSI-high metastatic colorectal cancer. The study had previously met its other dual primary endpoint of overall survival in the intent-to-treat population, which included all randomized patients regardless of the presence of active liver metastases, as reported in June 2025.

Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.

EXEL has collaborated with Merck to evaluate zanzalintinib, in combination with subcutaneous Keytruda Qlex in the planned phase III STELLAR-316 study for resected stage II/III colorectal cancer (CRC).

Under the agreement, Exelixis will sponsor the STELLAR-316 study, while Merck will provide Keytruda Qlex for use in the same. Keytruda is approved for several types of cancer.

Exelixis expects to initiate STELLAR-316 shortly, which will evaluate zanzalintinib with and without Keytruda Qlex in patients with resected stage II/III CRC who, following definitive therapy, have tested positive for molecular residual disease (MRD+) and have no radiographic evidence of disease — a high-risk population with substantial unmet need.

Earlier this year, Exelixis partnered with Natera, a global leader in cell-free DNA and precision medicine, for this study.

Natera will supply its Signatera assay to identify eligible MRD-positive patients for enrollment, further integrating precision medicine into the program.

The Merck partnership extends beyond colorectal cancer. In April 2026, Merck initiated the phase III LITESPARK-034 trial evaluating zanzalintinib plus Welireg versus Welireg and placebo in previously treated advanced RCC patients who progressed after PD-1/L1 and VEGFR-TKI therapies.

This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.

In May 2026, Exelixis announced the initiation of STELLAR-201, a phase II study evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies.
 

How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended upward during the past month.

VGM ScoresAt this time, Exelixis has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Exelixis has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerExelixis is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Biogen Inc. (BIIB - Free Report) , a stock from the same industry, has gained 8.8%. The company reported its results for the quarter ended June 2026 more than a month ago.

Biogen reported revenues of $2.74 billion in the last reported quarter, representing a year-over-year change of +3.4%. EPS of $3.60 for the same period compares with $5.47 a year ago.

For the current quarter, Biogen is expected to post earnings of $2.31 per share, indicating a change of -52% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.6% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Biogen. Also, the stock has a VGM Score of C.

Exelixis (EXEL - Free Report) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.81%. A quarter ago, it was expected that this drug developer would post earnings of $0.75 per share when it actually produced earnings of $0.87, delivering a surprise of +16%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Exelixis, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $628.69 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.99%. This compares to year-ago revenues of $568.26 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Exelixis shares have added about 27.8% since the beginning of the year versus the S&P 500's gain of 13%.

What's Next for Exelixis?While Exelixis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Exelixis was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.87 on $659.3 million in revenues for the coming quarter and $3.53 on $2.59 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Arcturus Therapeutics (ARCT - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This pharmaceutical company is expected to post quarterly loss of $1.07 per share in its upcoming report, which represents a year-over-year change of -214.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Arcturus Therapeutics' revenues are expected to be $2.51 million, down 91.1% from the year-ago quarter.